BlueWillow Biologics
BlueWillow Biologics is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented nanoemulsion platform. The platform, originally discovered at the University of Michigan, employs novel oil-in-water nano-droplets as an intranasal adjuvant that elicits a robust mucosal and balanced Th1/Th2 systemic immune response. This NanoVax® platform has established proof of concept in humans and enables intranasal vaccines for challenging respiratory infections, sexually transmitted infections and food allergies. The company’s lead candidates include intranasal vaccines for Covid-19, HSV-2, Peanut Allergy, RSV, Anthrax and pandemic influenza.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About us
Based on promising research generated under several Gates Foundation, NIH and DOD contracts, BlueWillow’s technology has been advanced significantly in recent years yielding several therapies in development.
BlueWillow’s lead NanoBio® Protect product is an alcohol-free, nasal antiseptic that has been shown to kill 99.99% of germs in lab tests. The FDA Over-the-Counter (OTC) product is applied by thoroughly swabbing the skin inside of each nostril and is recommended for use to help reduce germs on the skin that can cause infection. NanoBio® Protect is non-irritating, fragrance-free and leaves no residue after application. Other topical NanoBio® products are currently being developed for wounds and other skin ailments.
In parallel, BlueWillow Biologics is developing it’s proprietary NanoVax® platform to enable intranasal vaccines for challenging respiratory & sexually transmitted infections and intranasal immunotherapy (INIT) for food & respiratory allergies. The company’s lead candidates include intranasal vaccines for influenza, anthrax, RSV and HSV-2, and intranasal immunotherapy for peanut and milk allergy. The company’s NanoVax technology platform utilizes a novel oil-in-water emulsion adjuvant to enable intranasal vaccines and immunotherapy that elicit mucosal and systemic Th1/Th17 immunity. The NanoVax® platform uniquely elicits mucosal antibodies that serve as “bouncers at the door” as the body’s first line of defense against infections and allergens.
To date, over $190 million has been invested in developing BlueWillow’s nanotechnology platform. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.
Our novel intranasal NanoVax®adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Covid-19, pandemic flu, HSV, RSV, anthrax and peanut allergy.
In addition to the company’s lead NanoBio® Protect product, BlueWillow Biologics is developing its proprietary NanoVax® platform to enable intranasal vaccines for challenging respiratory & sexually transmitted infections and intranasal immunotherapy (INIT) for food & respiratory allergies. The company’s lead candidates include intranasal vaccines for influenza, anthrax, RSV and HSV-2, and intranasal immunotherapy for peanut and milk allergy. The company’s NanoVax® technology platform utilizes a novel oil-in-water emulsion adjuvant to enable intranasal vaccines and immunotherapy that elicit mucosal and systemic Th1/Th17 immunity. The NanoVax® platform uniquely elicits mucosal antibodies that serve as “bouncers at the door” as the body’s first line of defense against infections and allergens.